Encyclopedia entry · Metabolic Peptides
Mazdutide
Mazdutide (IBI362, LY3305677)
Mazdutide is a synthetic peptide acting as a dual agonist at the GLP-1 and glucagon receptors. Originally developed by Eli Lilly as LY3305677 and licensed to Innovent Biologics for Greater China development (under the code IBI362). Phase 3 trials in China have reported weight-management data and the compound is awaiting Chinese regulatory decision. UK status is investigational. Not licensed in the UK.
What the molecule is
- · Synthetic dual agonist of GLP-1 and glucagon receptors.
- · Originally developed by Eli Lilly (LY3305677), licensed to Innovent Biologics for China.
- · Mechanism extends GLP-1 class by adding glucagon-receptor activation for additional energy expenditure.
- · In Phase 3 trials in China for weight management and type 2 diabetes.
What the literature shows
- · Phase 3 trial data from Innovent Biologics in Chinese weight-management cohorts.
- · Phase 2 trial data in type 2 diabetes.
- · Comparator analyses against semaglutide monotherapy.
- · Mechanism work on dual GLP-1 / glucagon receptor activation.
UK regulatory status
- · Not a controlled drug under the Misuse of Drugs Act 1971.
- · Not scheduled under the Psychoactive Substances Act 2016.
- · No UK marketing authorisation as a medicine.
- · Investigational in the UK. Phase 3 development primarily based in China.
- · Research-tier in any non-trial UK sale context.
Where UK researchers source Mazdutide
See PeptideClear Trust Index →Ranked by CoA Trust tier (strong, partial, weak). Editorial commentary on retailers that list Mazdutide or compounds in the same category. We take no commission, referral fee or payment from anyone listed here.
Researchers wanting named-stack bundles (Wolverine, KLOW, Glow) and CoAs that can be QR-verified to a named third-party lab.
Research peptide retailer · Wolverine Stack £29.99, BPC-157 single from £14.99
Nottingham-based research peptide retailer (Bio Research Ltd, since 2024). Bundles and stacks are the hero SKU (Wolverine BPC-157 + TB-500, Tesamorelin + Ipamorelin 3:1, KLOW, Glow). Janoshik third-party CoAs published per batch with QR-code verification. 10-vial bulk packs alongside singles. Wholesale tier above 11 vials.
Researchers wanting GLP-1-adjacent compounds (Tirzepatide, Retatrutide, Mazdutide) inside a broader peptide catalogue, plus an adjacent biomarker blood-test service.
Research peptide retailer · BPC-157 £17.99, Tirzepatide from £42.99
Anti-counterfeit-framed UK research peptide retailer leaning hard on Fat Loss as primary nav category (Tirzepatide, Retatrutide, Mazdutide) alongside the broader catalogue. Above 99 percent HPLC and mass-spec verified purity claim. CoA gated by email request. Long-form pillar guides with named author byline and PubMed citations.
Buyers wanting peptides + SARMs + named-blend Peptide Sets from one supplier, and willing to arrange their own independent test via the named lab partner.
Research peptide retailer (peptides + SARMs) · £20.99 to £124.99 per vial
UK research peptide retailer + SARMs + Peptide Sets (dual-research blends). Site now says the founder has "worked within the peptide sector since 2012" (softened from an earlier "founded 2012" framing); trading entity Prime-Physique Ltd was incorporated August 2025. No founder names or university affiliation currently stated anywhere on-site (re-checked 18 Aug 2026, previously recorded as named). Independent testing partner Vanguard Laboratory (US) is now named, but no per-batch CoA is published or linked on product pages; customers are directed to commission their own test via Vanguard.
Buyers wanting a UK-billed GLP-Semaglutide research range, with an on-site reconstitution calculator and a clean shop UI.
Research peptide retailer · GLP-Semaglutide £80 to £220 per vial
UK research peptide retailer (Peptagenix UK Ltd, October 2024). Lead category is GLP-1 / Semaglutide. Inline reconstitution dose calculator on homepage. Mail-forwarding Covent Garden address. Athlete-facing framing alongside scientists and labs.
Where to learn more
- · PubMed search: "Mazdutide" and "IBI362 phase 3".
- · Innovent Biologics published clinical trial data.
- · Our function hub: Metabolic peptides.
- · Our /icb-rollout-tracker/ page for UK availability updates.
Clinical evidence record
Read the clinical evidence record for Mazdutide
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
PeptideClear does not sell, dispense, prescribe, or recommend Mazdutide for any specific person. This page is editorial commentary on the published preclinical and clinical research literature and the UK retail landscape.
Read our full methodology and how we are funded.